Compare VTEX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | MDXG |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.6M | 530.2M |
| IPO Year | 2019 | 2007 |
| Metric | VTEX | MDXG |
|---|---|---|
| Price | $3.63 | $3.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.97 | ★ $9.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $9.63 | $13.02 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $2.84 | $3.03 |
| 52 Week High | $6.82 | $7.99 |
| Indicator | VTEX | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 56.02 |
| Support Level | $2.92 | $3.45 |
| Resistance Level | $4.21 | $7.39 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 29.88 | 93.83 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.